Chromanone derivatives of the formula I ##STR1## in which R.sup.1 to R.sup.4 are each, independently of one another, H, A, CN, Hal, OR.sup.5, COOR.sup.5, CF.sub.3, OCF.sub.3, NO.sub.2, Ar, OAr, N(R.sup.5).sub.2 or CON(R.sup.5).sub.2, R.sup.5 is H or A, A is alkyl having 1 to 6 carbon atoms, Ar is phenyl which is unsubstituted or substituted by A, OR.sup.5, CN, Hal, CF.sub.3, OCF.sub.3, NO.sub.2 or N(R.sup.5).sub.2, Hal is F, Cl, Br or I, and their salts, are suitable as intermediates in the synthesis of medicaments.
A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.
Compounds of formula I or pharmaceutically acceptable salts thereof are provided: ##STR00001## wherein each of R.sup.1, R.sup.2, R.sup.3, R.sup.4, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
Compounds of Formula 1 or pharmaceutically acceptable salts thereof are provided: ##STR00001## which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
